Company Filing History:
4 out of 816 
2 out of 3,477 
1 out of 45 
Years Active: 2015-2024
Title: **Yoshiharu Sakai: A Pioneer in Monoclonal Antibody Research**
Introduction
Yoshiharu Sakai is a distinguished inventor based in Kyoto, Japan, known for his significant contributions to the field of biomedical research. With a total of four patents to his name, Sakai's innovative work focuses primarily on monoclonal antibodies and cancer prognosis methods.
Latest Patents
One of Sakai's latest patents is for an "Anti-human CCR1 monoclonal antibody." This invention includes a monoclonal antibody that binds to the human CC chemokine receptor 1 (CCR1), effectively inhibiting its activation. The antibody specifically targets an extracellular region of CCR1, blocking its interaction with CC chemokine ligand 15 (CCL15). This patent also encompasses various components such as antibody fragments, hybridomas producing the antibody, nucleic acids encoding the antibody, and methods for producing the antibody or fragments thereof.
Another notable invention is a "Method for determining prognosis of cancer," which involves detecting the phosphorylation of a tyrosine residue at position 2681 of TRIO in samples obtained from subjects. This method serves as a crucial approach for predicting cancer outcomes.
Career Highlights
Throughout his career, Yoshiharu Sakai has held positions at esteemed institutions, including Kyoto University and Toray Industries, Inc. His work at these organizations has positioned him at the forefront of research in antibody technology and cancer diagnostics.
Collaborations
Sakai has collaborated with notable peers such as Yoshinori Tanaka and Satoko Kanamori. These partnerships have fostered a collaborative environment, enriching the research landscape and leading to impactful discoveries.
Conclusion
Yoshiharu Sakai stands out as a pivotal figure in the realm of biomedical innovations. His patents reflect a deep commitment to advancing therapeutic and diagnostic strategies, particularly in the treatment of CCR1-related diseases and cancer prognosis. His contributions continue to inspire future research and innovation in the field.